MergerJul 28, 2026, 05:16 PM
Yarrow Bioscience Completes Merger, Begins Trading as YARW
AI Summary
Yarrow Bioscience, Inc. (formerly VYNE Therapeutics Inc.) announced the completion of its merger with Pre-Merger Yarrow Bioscience. The combined company, now named Yarrow Bioscience, Inc., will trade on Nasdaq under the ticker symbol "YARW" starting July 28, 2026. This strategic move was supported by approximately $200 million in private financings, extending the company's cash runway into 2028. The company is focused on advancing YB-101, a potential first-in-class anti-TSHR antibody for Graves' disease and thyroid eye disease, with Phase 2a data expected in 2H 2027.
Key Highlights
- Merger between VYNE Therapeutics and Pre-Merger Yarrow Bioscience completed on July 27, 2026.
- VYNE Therapeutics changed its name to Yarrow Bioscience, Inc. and will trade under the ticker symbol "YARW".
- Private financings totaling approximately $200 million were completed, providing cash runway into 2028.
- A 1-for-50 reverse stock split of VYNE common stock was effected on July 24, 2026.
- VYNE distributed a special cash dividend of $17.3 million, or $0.40242 per share.
- The combined company has approximately 2.8 million shares of common stock outstanding.
- Phase 2a data for YB-101 in Graves' Disease is expected in the second half of 2027.
- Data from GenSci's Phase 1 TED trial (MAD portion) are anticipated in the second half of 2027.
Price Impact
More from VYNE